Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20366 (
substance P
)
21,176
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The endogenous peptides somatostatin (
SRIF
) and
substance P
comprise very different structures. Although both bind G-protein-coupled receptors, the
SRIF
receptors (SSTR 1-5) recognize
SRIF
and related peptides which retain its beta-turn such as the potent cyclic hexapeptide
SRIF
agonist L-363,301 (6a), but not
substance P
. Conversely the NK-1 receptor binds
substance P
but not the above ligands. In contrast, the beta-D-glucosides 1 and 2, designed to mimic the beta-turn of 6a, bind both receptors. This observation led us to attempt the conversion of 6a into the first potent, selective cyclic hexapeptide ligand for the NK-1 receptor. To this end, we combined design with a minilibrary approach. The goal was accomplished with surprising ease, leading to the NK-1 receptor antagonist 9 (IC50 2.0 +/- 0.4 nM). This demonstrates that peptidomimetics, incorporating in this case the promiscuous beta-D-glucose scaffold, can provide valuable clues about receptor similarities not revealed by their endogenous ligands. In addition, this work suggests that the use of libraries and rational design need not be mutually exclusive approaches to lead discovery.
...
PMID:Synthesis of potent cyclic hexapeptide NK-1 antagonists. Use of a minilibrary in transforming a peptidal somatostatin receptor ligand into an NK-1 receptor ligand via a polyvalent peptidomimetic. 869 40
The role of somatostatin (
SRIF
) in controlling the granulomatous inflammatory response to infection with the parasite Schistosoma mansoni was explored in mice. The murine granulomas contain
SRIF
-14. Immunoreactive
SRIF
and prepro
SRIF
localize in the cytoplasmic granules of macrophages within the granulomas. The granulomas contain mRNA for prepro
SRIF
and are not innervated. The production of
SRIF
by the inflammatory cells appears to be inducible. The granulomas contain mRNA for the
SRIF
receptors sst2A and sst2B, which are expressed mainly on CD4- T lymphocytes and bind
SRIF
-14 with high affinity. Antigens from the schistosome eggs stimulate granuloma T lymphocytes to produce cytokines. Interferon-gamma (IFN-gamma) is one such cytokine made by CD4+ T lymphocytes.
SRIF
-14 suppresses antigen-induced IFN-gamma production from granuloma cells, and this effect is blocked by anti-sst2 antibody.
SRIF
was shown to inhibit IFN-gamma-induced immunoglobulin G2a (lgG2a) synthesis in murine schistosomiasis.
SRIF
also blocks
substance P
(SP)-stimulated IFN-gamma and lgG2a secretion. Schistosome-infected animals treated with the
SRIF
analog octreotide form smaller granulomas that secrete substantially less IFN-gamma and lgG2a. Unpublished observations suggest that
SRIF
does not modulate schistosome egg antigen- or concanavalin A-stimulated granuloma lymphocyte proliferation in murine schistosomiasis. In conclusion,
SRIF
may be an important factor in the control of the granulomatous inflammatory response in murine schistosomiasis.
...
PMID:Granulomas in murine schistosomiasis mansoni have a somatostatin immunoregulatory circuit. 876 93
There is increasing evidence that neuropeptides have trophic functions during embryogenesis. We examined the ability of angiotensin II,
substance P
,
somatostatin-28
and luteinising hormone-releasing hormone to influence neurite outgrowth from embryonic chick sympathetic neurons in culture. Nanomolar concentrations of angiotensin II inhibited neurite outgrowth, whereas the other peptides had no effect at similar concentrations. The effect of angiotensin II on neurite outgrowth is likely to be mediated by an atypical angiotensin receptor, as it was only weakly inhibited by [sar1,ala8]angiotensin II, and was not inhibited by losartan, an inhibitor of mammalian AT1 receptors, or PD123319, an AT2 inhibitor. Neurite outgrowth was also inhibited by angiotensin III and angiotensin IV but not by angiotensinogen I1-14. The study provides further evidence that angiotensin peptides, like classical neurotransmitters, may have trophic functions during embryogenesis.
...
PMID:A novel action of angiotensin peptides in inhibiting neurite outgrowth from isolated chick sympathetic neurons in culture. 880 32
The presence and distribution of the neuropeptides VIP (vasoactive intestinal polypeptide), NPY (neuropeptide tyrosine), SP (
substance P
), GAL (galanin), SST-14 (
somatostatin-14
) and SST-28 (
somatostatin-28
), were investigated in the rat urinary bladder by light microscopy immunohistochemistry. The peptides were essentially present in the fundus and corpus of the bladder wall, in particular in the muscle coat. NPY and VIP were most readily detected, and were sometimes co-localized in the muscle layer and around many blood vessels, SP was present essentially in the submucosa, and GAL in the muscle layer. SST was observed, albeit rarely, at the base of the urinary bladder: only SST-14 was present in the muscle layer; SST-28 was not revealed by immunohistochemistry.
...
PMID:Distribution of different neuropeptides in the rat urinary bladder. 883 8
The aim of this investigation was to purify aminopeptidase M (APM) from the muscle layer of the small intestine, to compare it with APM of the mucosa and kidney, and to examine the degradation of gastrointestinal neural and hormonal peptides by muscle APM. APM was purified from the muscle and mucosa of the pig small intestine by DEAE-Sepharose and immuno-affinity chromatography. The specific activity of APM from muscle, mucosa, and kidney was 3900, 3000, and 3800 nmol/min per mg protein, respectively (substrate [Leu5]enkephalin). Muscle and mucosa APM contained four protein bands with apparent molecular weights of 150, 110, 73, and 52 kDa. Kidney APM contained three protein bands of 150, 110, and 56 kDa. The 150, 110, and 52/56 kDa bands cross-rected with an APM antiserum. APM from each tissue degraded [Leu5]enkephalin and [Met5]enkephalin, but not cholecystokinin-8, gastrin releasing peptide-10,
somatostatin-14
,
substance P
, and vasoactive intestinal peptide. The enzymes were identically inhibited by APM antiserum, amastatin, bestatin, actinonin, and 1, 10 phenanthroline. Non-mucosal APM may degrade enkephalins and terminate their biological actions.
...
PMID:Purification and characterization of aminopeptidase M from muscle and mucosa of the pig intestine. 896 85
Patients with Huntington's disease (HD) develop pathological changes in cerebral cortex as well as in striatum. We studied levels of neuropeptide immunoreactivity in 13 areas of postmortem cerebral cortex dissected from 24 cases of HD and 12 controls. Concentrations of immunoreactive cholecystokinin (CCK-LI) were consistently elevated 57 to 153% in HD cortex. Levels of vasoactive intestinal polypeptide (VIP-LI) and neuropeptide Y (NPY-LI) were significantly increased in 10 and 8 of the 13 cortical regions, respectively. Concentrations of somatostatin (
SRIF
-LI) were increased in only 3 areas, while
substance P
(SP-LI) was, for the most part, unchanged. Detailed analyses of the CCK-LI and VIP-LI data showed there to be no relationship between the increased cortical peptide levels and the degree of striatal atrophy. We studied the same cortical peptides in rats with long-standing striatal lesions and found no significant changes of CCK-LI, NPY-LI, VIP-LI, or
SRIF
-LI in any of the 8 cortical regions that were examined. These results indicate that there are widespread and differential changes in cortical neuropeptide systems in HD and that these changes occur independently of the striatal pathology that characterizes the illness.
...
PMID:Cortical peptide changes in Huntington's disease may be independent of striatal degeneration. 912 12
The distribution of seven neuropeptides was studied in the cat amygdala using an indirect immunoperoxidase technique. No labeling was found for luteinizing hormone-releasing hormone or beta-endorphin (1-27). Sparse alpha-melanocyte-stimulating hormone-immunoreactive fibers were found in the basomedial nucleus of the amygdala, whereas a low density of fibers containing alpha-neo-endorphin was observed in the anterior amygdaloid area. Neurotensin was observed in fibers of the anterior amygdaloid area (low density) and both the lateral (low density) and the medial part (moderate density) of the central nucleus. A low density of fibers containing
neurokinin A
was found in the anterior amygdaloid area, the basolateral nucleus, and the medial part of the central nucleus. A moderate density was observed in the basomedial nucleus and in the medial and cortical nuclei. Fibers containing
somatostatin-28
(fragment 1-12) were observed in all the amygdaloid nuclei, whereas immunoreactive cell bodies were found in all the nuclei except in the medial part of the central nucleus and the medial nucleus. Perikarya containing
neurokinin A
were observed in the latter nucleus. The results point to a discrete distribution of peptidergic fibers in the cat amygdala, as well as the occurrence of neurons containing
neurokinin A
and
somatostatin-28
(fragment 1-12). The distribution of the peptides studied in the cat is compared with the location of the same peptides in the amygdala of other species. The possible diencephalic origin of the peptidergic fibers is also discussed.
...
PMID:Neuropeptides in the cat amygdala. 958 Feb 15
Intrathecal administration of octreotide, a stable somatostatin analogue, provides pain relief in patients, and locally applied somatostatin inhibits firing of nociceptive dorsal horn neurons. In the present study, we have raised polyclonal antibodies that specifically detect the somatostatin receptor sst2A and used these antisera for immunocytochemical localization of the receptor protein in the rat spinal cord and dorsal root ganglia. In the superficial layers of the dorsal horn, sst2A-like immunoreactivity (Li) formed a dense network consisting of neuronal perikarya and dendrites which were often closely apposed by, but not co-contained within,
somatostatin-14
-immunoreactive nerve fibres and terminals. sst2A-Li was resistant to dorsal rhizotomy and did not colocalize with either
substance P
or calcitonin gene-related peptide suggesting that sst2A-Li was not located to primary afferents, but rather confined to second-order spinal neurons. The position of sst2A-Li perikarya and dendrites in the dorsal horn appeared to be similar to those containing mu-opioid receptor-Li; however, double labelling experiments revealed no instances of coexistence of these two receptors. sst2A-Li was also observed in the dorsal root ganglia predominantly targeted to the somatic plasmalemma of medium size neurons distinct from those expressing
somatostatin-14
or delta-opioid receptors. Thus, the present results not only provide a morphological substrate for spinal octreotide analgesia but also show that somatostatin and opioids are poised to modulate nociceptive transmission by distinct anatomical systems.
...
PMID:Immunocytochemical localization of somatostatin receptor sst2A in the rat spinal cord and dorsal root ganglia. 987 49
Although it is well known that somatostatin (
SRIF
) modulates several digestive functions, there are only a few reports about its effect on the salivary glands. Here, the action of
SRIF
parotid secretion was studied, in vivo and in vitro, in male Wistar rats. In vivo
SRIF
infusion (35 microg/kg per hr) inhibited the parotid flow rate stimulated by methacholine,
substance P
and noradrenaline. The isoprenaline-stimulated flow rate was also decreased by
SRIF
, but only at highest dose of the secretory agent. Total protein and amylase secretion were studied.
SRIF
inhibited the total protein secretion stimulated by the above-mentioned agents, except that by isoprenaline.
SRIF
did not inhibit in vivo amylase secretion. In order to avoid flow-rate interference with total protein and amylase measurements, in vitro experiments were performed.
SRIF
(25 nM) strongly inhibited the total protein release stimulated by methacholine (5.1 microM), noradrenaline (19 microM), and
substance P
(10 microM). The inhibitory effect was not raised by the absence of calcium in the incubation medium. However, in vitro amylase release was not affected by
SRIF
. It was concluded that
SRIF
modulates rat parotid secretion stimulated by cholinergic, adrenergic and peptidergic agents, acting on any step in the calcium pathway.
...
PMID:Modulation by somatostatin of rat parotid salivary secretion stimulated by cholinergic, adrenergic and peptidergic agents. 1041 70
The traditional view that Testudines (tortoises and turtles) should be regarded as the surviving clade of the anapsid reptiles rather than classified with the diapsid reptiles (snakes, lizards, and crocodiles) has recently been challenged. Neuropeptide Y,
neuropeptide gamma
, and
somatostatin-14
were isolated from an extract of the brain,
substance P
and galanin from an extract of the intestine, and insulin and pancreatic polypeptide from an extract of the pancreas of the desert tortoise, Gopherus agassizii. Despite that crocodilians did not appear until the late Triassic, the amino acid sequences of the tortoise peptides resemble those of the American alligator quite closely. The primary structures of neuropeptide Y,
somatostatin-14
, and
neuropeptide gamma
are the same in tortoise and alligator. The primary structures of
substance P
, insulin, galanin, and pancreatic polypeptide in the two species differ by 1, 3, 5, and 8 amino acid residues, respectively. Although fewer neurohormonal peptides from squamates (lizards and snakes) have been characterized, the primary structures of
neuropeptide gamma
, insulin, and pancreatic polypeptide from the Burmese python and the desert tortoise differ by 3, 8, and 18 residues, respectively. The data suggest, therefore, a closer phylogenetic relationship between Testudines and Crocodilians than that derived from 'classical' analyses based on morphological criteria and the fossil record.
...
PMID:Neuroendocrine peptides (insulin, pancreatic polypeptide, neuropeptide Y, galanin, somatostatin, substance P, and neuropeptide gamma) from the desert tortoise, Gopherus agassizii. 1047 26
<< Previous
1
2
3
4
5
6
7
8
9
Next >>